Texas Oncology - Northeast Texas

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Metastatic breast cancer2 trials
• Colorectal cancer1 trial
• Gastric and oesophageal cancer1 trial
• Myelodysplastic syndromes1 trial

Phase

• Phase 35 trials
• Phase 2/32 trials
• Phase 1/21 trial
• Phase 21 trial

Status

• Recruiting7 trials
• Active, not recruiting2 trials

Lead sponsor

• Pfizer6 trials
• Bristol-Myers Squibb1 trial
• SCRI Development Innovations, LLC1 trial
• Takeda1 trial

Running trials

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source

  Contact: Amir Faridi, Site 0415

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

  NCT07226999· Phase 2/3· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

  NCT06966453· Phase 1/2· Pfizer· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

  Contact: Amir Faridi (principal investigator)

• Active, not recruiting

  BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

  NCT06773910· Phase 2· SCRI Development Innovations, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Colorectal cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Myelodysplastic syndromes1 recruiting